cyrilzakka/clinical-trials huggingface dataset:
Plant-Based Defaults

In this study, participants at six different academic events were randomly assigned to one of two conditions: (1) a default meat group, where the default choice was a meal with meat and participants had the option of opting out and choosing a plant-based meal; and (2) a default veg group, where the default choice was a plant-based meal with the option of opting out and choosing a meal with meat. Based on the success of prior studies that implemented plant-based defaults through preselection, we hypothesized that more participants would choose the plant-based meal when that option was set as the default, and we hypothesized that the default intervention would be equally effective across academic institutions. We also hypothesized that the default intervention would be equally effective across demographic groups, which would help to further demonstrate the generalizability of our plant-based default intervention.


Eligibility Criteria:
Inclusion Criteria:

* Academic event attendee

Exclusion Criteria:

* None
Effect of Loaded Functional Training on Hemiplegic Cerebral Palsy

weakness of lower limb is common in cp children


Eligibility Criteria:
Inclusion Criteria:

* age 10-12
* level I,II according to GMFCM
* Able to follow and understand instructions

Exclusion Criteria:

* visual and respiratory disorder
Atrasentan in Treating Patients With Prostate Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.

OBJECTIVES:

* Determine the safety of atrasentan in patients with hormone-refractory prostate cancer.
* Determine the pharmacokinetics of this drug in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral atrasentan once daily for 3 years in the absence of disease progression or unacceptable toxicity.

Patients are followed at 1 month and then every 3 months for 2 years.

PROJECTED ACCRUAL: Approximately 1,400 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of hormone-refractory prostate cancer
* Completed protocol ABBOTT-M00-211 or ABBOTT-M00-244 within the past 30 days

  * Disease progression OR
  * Active in trial when double-blind treatment period ended

PATIENT CHARACTERISTICS:

Age

* 19 and over

Performance status

* Karnofsky 60-100%

Life expectancy

* Not specified

Hematopoietic

* WBC at least 3,000/mm3
* Absolute neutrophil count greater than 1,000/mm3
* Platelet count at least 100,000/mm3
* Hemoglobin at least 9 g/dL

Hepatic

* Bilirubin less than 1.5 mg/dL
* AST and ALT no greater than 1.5 times upper limit of normal

Renal

* Creatinine clearance at least 40 mL/min

Cardiovascular

* No New York Heart Association class II-IV heart disease

Pulmonary

* No significant pulmonary disease requiring chronic or pulse steroid therapy within the past 3 months

Other

* Fertile patients must use 2 effective methods of contraception (1 must be barrier contraception) during and for 8 weeks after study
* No reason that would preclude study
* No significant comorbid condition that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* At least 4 weeks since other prior cytotoxic chemotherapy
* No other concurrent cytotoxic chemotherapy

Endocrine therapy

* Not specified

Radiotherapy

* At least 4 weeks since prior radionuclides
* No concurrent radionuclides

Surgery

* Not specified

Other

* At least 4 weeks since prior investigational agents
* No concurrent antiretroviral therapy for HIV-positive patients
* No concurrent participation in another investigational study
Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.


Eligibility Criteria:
Inclusion Criteria:

* Age\> 18 years old
* Performance Status 0-2
* Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy
* Treatment termination time greater than 6 months at inclusion
* Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3
* Patient in complete remission at inclusion
* patient's consent's obtained after information

Exclusion Criteria:

* Previous treatment for upper aerodigestive tract cancer
* Incomplete radiotherapyTreatment
* Neurological pathology wich may affect the functions of the upper aerodigestive tract
* Pregnant or breastfeeding woman
* Unweaned alcoholism
* Tracheotomized patient at the time of the study
* Patient under protection: subjects with guardianship or under law protection
* No health insurance coverage
Molecular Basis of the Growth Axis in Short Stature

To examine the clinical genetic and biochemical characteristics of children with growth hormone deficiency.


Eligibility Criteria:
Inclusion Criteria:

* Patient with growth hormone deficiency
Genomic Translation for Amyotrophic Lateral Sclerosis Care

The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern.

In all patients, ALS/MND is caused by the progressive death of motor neurons. However, every patient is affected differently. Some develop symptoms in their 80's while others get sick in adolescence. Swallowing/speech are affected first in some patients, but most have weakness in their hands or feet at onset. Some individuals show very rapid progression, even as others live for decades. Finally, some patients have loss of mainly motor neurons in the brain (as in primary lateral sclerosis), while others lose mainly lower motor neurons in the spinal cord and brain stem (as in progressive muscular atrophy). Research has uncovered a few genetic factors that contribute to the variability of ALS/MND. For example, mutations in the superoxide dismutase 1 (SOD1) gene makes onset in the legs more likely and decreases the chance of developing dementia. Conversely, having a mutated C9ORF72 gene makes dementia much more likely. Uncovering additional factors causing ALS variability is an important research priority and is likely to provide clues about how to better diagnose and treat the disease.

This study is called "Genomic Translation for ALS Care" (GTAC). The investigators will analyze the genome and gene expression patterns of people with ALS/MND and carry out research on that data, finding insights that the investigators hope will translate into better care for ALS/MND patients.

Eligibility Criteria:
Inclusion Criteria:

Study participants meeting all of the following criteria will be eligible for enrollment in GTAC:

1. Men or women of any race or ethnicity aged 18 or older
2. Diagnosis of familial or sporadic ALS (definite, probable, or possible according to El Escorial Criteria, Appendix 1), or those with primary lateral sclerosis or progressive bulbar/muscular atrophy forms of motor neuron disease. All-comers with ALS/MND should be enrolled without regard to familial vs sporadic or gene mutation status (i.e. participants with known gene mutations should still be enrolled), or phenotype.
3. Capable of providing informed consent and following study procedures (in the case that a subject lacks the ability to provide informed consent, informed consent will be sought from the subject's surrogate representative).
4. Willing to return to clinic site (or another participating center) for follow-up care.

Exclusion Criteria:

Study participants meeting any of the following criteria during screening evaluation will be excluded from enrolling in GTAC:

1. Invasive ventilation (i.e. tracheostomy) in place.
2. Non-invasive ventilation dependent (defined as \>22 hours per day)
3. Pregnancy.
4. Known Human Immunodeficiency Virus (HIV) , chronic Hepatitis B, or Hepatitis C (because cells will be frozen down for future cell line generation).
Surgical Assessment Tool for Ethiopia National Policy Monitoring & Evaluation

Introduction: A baseline assessment of surgical capacity is recommended as a first-step to inform national policy on surgical system strengthening. In Ethiopia, the World Health Organization's Situational Analysis Tool (WHO SAT) was adapted to assess surgical capacity as part of a national initiative: Saving Lives Through Safe Surgery (SaLTS). This study describes the process of adapting this tool and initial results.

Methods: The new tool was used to evaluate fourteen hospitals in the Southern Nations, Nationalities, and People's Region of Ethiopia between February and March 2017. Two analytic methods were employed. To compare this data to international metrics, the WHO Service Availability and Readiness Assessment (SARA) framework was used. To assess congruence with national policy, data was evaluated against Ethiopian SaLTS targets.


Eligibility Criteria:
Inclusion Criteria:

* Fourteen public hospitals (11 primary, 1 general, and 2 specialized) chosen by the regional health bureau
* Hospital staff with willingness to participate in study
* Hospital staff with availability to participate in study

Exclusion Criteria:

* Hospital staff which did not volunteer to participate or refused to participate were excluded.
* Hospital staff not available at the time of visit
* Hospitals not chosen by the regional health bureau
Validity and Reliability of Indonesian Translated Ages and Stages Questionnaires - Third Edition (ASQ-3) as a Screening Tool for Developmental Delay in 1-12 Months Old Children

This study aimed to provide the validity and reliability of the Indonesian ASQ-3 questionnaires as a screening tool for developmentally delayed children aged less than one year old. This study was divided into 2 phases. The first phase (April-June 2018) included the transcultural adaptation of the ASQ-3 questionnaires for 2 to 12 months age groups from English to Indonesian. The second phase (July- September 2018) included a cross-sectional study of Indonesian ASQ-3 questionnaires for parents/caregivers of children aged 1-12 months, with 35 children in each age group by cluster sampling methods, in 2 district areas in East Jakarta.


Eligibility Criteria:
Inclusion Criteria:

* Parents with children aged 1-12 months
* Parents who finished at least elementary school

Exclusion Criteria:

* Parents with communication difficulties
* Parents who could not speak Indonesian language
Optimum Dose of Remifentanil for Intubation in Small Children

The routine medications to relax the muscles of the throat are an anesthetic drug, propofol, in combination with an ultra short acting pain medicine, remifentanil. Remifentanil is used to reduce the amount of propofol required but also to decrease the natural cough reflex to the breathing tube being inserted.The purpose of this study is to find the dose of remifentanil when combined with propofol which provides the best conditions for intubation without cough in infants and small children.Younger children may need higher doses of Remifentanil to facilitate intubation as they are more tolerant to the respiratory depressant effect of Remifentanil.

The introduction of propofol and short acting opioids has allowed intubation without the use of NMBA to become routine practice. The combination of an opioid and propofol reduces laryngeal reflexes and decreases pressor response to intubation. Identification of the optimum dose combination and sequence of remifentanil-propofol for intubation would allow clinicians to abandon the use of non depolarizing muscle relaxants.Younger children may need higher doses of Remifentanil to facilitate intubation as they are more tolerant to the respiratory depressant effect of Remifentanil. The Remifentanil dose will be prepared in a standard fashion by an anesthesiologist not directly involved in the study from the data given to them by a research assistant. The anesthesiologists performing laryngoscopy will be one of the four investigators. There will be a standard starting dose, which must be as close to the population mean as possible. All subjects will receive a minimum dose of 1µg/kg remifentanil which has been shown to produce acceptable intubating conditions.

The dose of remifentanil for the following subject in each group will be determined from the dose used in the previous subject and response to intubation using an" up and down" sequential-allocation technique described by Dixon.

The mean remifentanil intubation dose will be obtained by calculating the midpoint concentration of all independent pairs of patients involving a crossover (ie. Intubation scores all1 to intubation scores not all 1). Mean remifentanil intubation dose would be the average of the crossover midpoints in each subgroup. In addition the standard deviation of remifentanil dose will be the standard deviation of the crossover midpoints in each group. Patient demographics (age/sex/weight), and time to return of spontaneous ventilation will be expressed as mean +/- standard deviation. The inter-group comparisons will be performed using analysis of variance with a difference of 0.5 µg/kg considered to be significant and a p\<0.05 considered statistically significant.

Eligibility Criteria:
Inclusion Criteria:

* Presenting for routine endotracheal intubation under anesthesia.
Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation

In France, the Afssaps is the body in charge of the evaluation of pharmacodependance. In order to fulfil its mission, the Afssaps has created a network of 11 Centres for Evaluation and Information on Pharmacodependance (CEIP), coordinated by the Drugs and Psychotropics Unit. Pharmacodependence notifications issued by professionals are collected by each Centre which evaluates them. Nantes' CEIP created an original tool to harmonize case reporting and make it possible to homogeneously evaluate the seriousness of pharmacodependence cases as each CEIP had his own way of analysing his cases. The aim of this study is to assess this tool.


Eligibility Criteria:
Inclusion Criteria:

* case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
Validation of 70-gene MammaPrint Profile in Japanese Population

By using gene-expression profiling, Van't Veer and colleagues developed a 70-gene prognosis profile, MammaPrint, to identify breast cancer patients who are at low risk of developing distant metastases and therefore might safely be spared chemotherapy. The aim of this study is to evaluate the prognostic value of the 70-gene Mammaprint profile in Japanese women with node-negative breast cancer.

Frozen tumor samples from 140 node-negative, breast cancer patients aged between 29 and 70 years at diagnosis are hybridized on MammaPrint array. Patients were treated with breast conserving therapy or mastectomy with axillary lymph node dissection between December 1998 and August 2001 at Osaka Medical Center for Cancer and Cardiovascular Diseases. Samples are evaluated by gene expression profiling for the 70-gene MammaPrint profile and classified as genomic high risk or genomic low risk.

Eligibility Criteria:
Inclusion Criteria:

* Breast cancer patients
* Node-negative
* Treated with breast conserving therapy or mastectomy with axillary lymph node dissection at Osaka Medical Center for Cancer and Cardiovascular Diseases
Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Er Laser for the Treatment of Androgenetic Alopecia

Laser sources have established their potential effect in inducing hair regrowth. No study has compared the effect of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (AGA).

The investigators performed a prospective study between to compare the efficacy and safety of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (AGA). The efficacy of the two therapies was evaluated by the investigator's Global Assessment (IGA) scores and the patient's Likert satisfaction scale at week 12 and week 24. Changes in total, terminal and villous hair count, total and terminal hair diameter, and AGA grade were also recorded. Adverse events were evaluated at each follow-up.

Eligibility Criteria:
Inclusion Criteria:

* age between 18 and 65 years;；
* clinical diagnosis of AGA；
* AGA diagnosis was evaluated following Norwood Hamilton grade II-V criteria；
* no previous laser treatments for AGA in the past six months before enrollment；
* willingness to provide pictures and follow-up studies.

Exclusion Criteria:

* if presented with severe diseases of internal organs, eyes, or skin;
* inflammation, infection, or unhealed wounds on the skin around the site of treatment on the head;
* systematic treatment with corticosteroids or other immunosuppressants and immunomodulators in the past 3 months
Heated High Flow Oxygen Use in Infants With Bronchiolitis and Hypoxia

Bronchiolitis is a common cold weather seasonal respiratory illness affecting infants and children. Multiple supportive therapies have been tried in infants with bronchiolitis including albuterol, racemic epinephrine, hypertonic saline nebulization, but to date supportive therapy with oxygen is the only proven therapy to decrease respiratory distress in infants with bronchiolitis, with hypertonic saline showing a borderline statistically significant improvement. This prospective, randomized study will compare CSS and PEWS scores on infants who receive oxygen by standard flow nasal cannula and to those who receive oxygen via Humidified High-Flow Nasal Cannula (HHFNC). The results will help determine if infants with viral bronchiolitis who receive humidified high flow nasal cannula oxygen therapy have improved Clinical Severity Score (CSS) and Pediatric Early Warning System (PEWS) scores and ultimately decreased lengths of admissions when compared to patients treated with nasal cannula oxygen therapy with/without bronchodilator therapy.

Hypothesis Heated Humidified High-flow Nasal Cannula Delivery of Oxygen decreases respiratory distress as measured by pediatric CSS and PEWS when compared with routine nasal cannula oxygen delivery in infants with bronchiolitis.


Eligibility Criteria:
Inclusion Criteria:

1. Are previously healthy infants ages 3 months to 18 months of age
2. Have O2 saturations of \< 92% on room air while awake
3. Have a clinical diagnosis of bronchiolitis
4. Have a CSS score showing moderate distress \>4
5. Have a planned admission to the hospital for either inpatient or observation status
6. Have parental consent to enroll in study

Exclusion Criteria:

1. Have significant apnea or bradycardia events reported by parent or witnessed in Emergency Department
2. Have prior airway disease diagnosis other than URI within the previous two months
3. Were previously intubated; previously having had airway bronchoscopy or surgery
4. They are ex-preemies, i.e. had an estimated gestational age of \<37 weeks at time of birth
5. Have a diagnosis of lobar consolidation or round pneumonia by Chest x-ray
6. Have pleural disease by chest x-ray
7. Have history of cardiac disease, renal disease, hematologic disease such as sickle cell disease or leukemia, congenital hemoglobinopathies or Congenital Adrenal Hyperplasia
8. Have undergone prior radiation or chemotherapy
9. Have functional or anatomical bowel obstruction as demonstrated by persistent vomiting or tensely distended abdomen
10. Have history of Choanal atresia or cleft palate
11. Have history of neuromuscular disorder, e.g., Spinal muscular atrophy, muscular dystrophies, cerebral palsy or hypotonia
12. Have impending respiratory failure as demonstrated by blood gas with pCO2 of greater than 60 or apnea spells lasting greater than 30 seconds
Pepsinogen-1 Serum Levels in Hyperemesis Gravidarum

In this study, the investigators planned to investigate maternal serum pepsinogen-1 (MSPG-1) levels in pregnant women with severe hyperemesis gravidarum (HG) and pregnant women without severe HG.

HG is the most common cause of hospitalization in the first trimester of pregnancy and represents an economic burden on the healthcare system. Therefore, our aim in this study was to investigate whether there is a statistical difference in MSPG-1 levels between pregnant women with severe HG and pregnant women without severe HG and to determine a cut-off value for MSPG-1 levels for the indication of hospitalization of pregnant women with HG.

The study poses no risk to the pregnant woman or the fetus.

The study will enroll pregnant women in the first trimester with maternal age between 21 and 35 years who were diagnosed with hyperemesis gravidarum and had no fetal congenital or chromosomal abnormalities and who were admitted to the perinatology outpatient clinic of Etlik City Hospital. The investigators will include 40 cases with no signs and diagnosis of systemic maternal disease and no chronic drug use as a case group and 40 healthy pregnant women matched for age, gestational week and body mass index as a control group.

Eligibility Criteria:
Inclusion Criteria:

* A singleton pregnancy
* Between 21 and 35 years old
* Diagnosis of hyperemesis gravidarum

Exclusion Criteria:

* Multiple pregnancy
* Fetal congenital and chromosomal abnormalities
* Chronic drug use, alcohol and smoking
* Pregnant women with diabetes or obesity, peptic ulcer or gastritis, liver and/or gallbladder disease (cholangitis or gallstones), thyroid dysfunction, urinary tract infection, celiac disease, cardiovascular or renal disease